Topic
Betamethasone
About: Betamethasone is a research topic. Over the lifetime, 2581 publications have been published within this topic receiving 56698 citations. The topic is also known as: SCH-4831 & Rinderon.
Papers published on a yearly basis
1 / 2
Papers
TL;DR: Preliminary evidence justifies further trials, but that further work is needed before any new routine procedure is established, as there may be an increased risk of fetal death in pregnancies complicated by severe hypertensionedema-proteinuria syndromes and treated with betamethasone.
Abstract: A controlled trial of betamethasone therapy was carried out in 282 mothers in whom premature delivery threatened or was planned before 37 weeks9 gestation, in the hope of reducing the incidence of neonatal respiratory distress syndrome by accelerating functional maturation of the fetal lung. Two hundred and thirteen mothers were in spontaneous premature labor. When necessary, ethanol or salbutamol infusions were used to delay delivery while steroid or placebo therapy was given. Delay for at least 24 hours was achieved in 77% of the mothers. In these unplanned deliveries, early neonatal mortality was 3.2% in the treated group and 15.0% in the controls (p 0.01). There were no deaths with hyaline membrane disease or intraventricular cerebral hemorrhage in infants of mothers who had received betamethasone for at least 24 hours before delivery. The respiratory distress syndrome occurred less often in treated babies (9.0%) than in controls (25.8%, p 0.003), but the difference was confined to babies of under 32 weeks9 gestation who had been treated for at least 24 hours before delivery (11.8% of the treated babies compared with 69.6% of the control babies p. 0.02). There may be an increased risk of fetal death in pregnancies complicated by severe hypertensionedema-proteinuria syndromes and treated with betamethasone, but no other hazard of steroid therapy was noted. We conclude that this preliminary evidence justifies further trials, but that further work is needed before any new routine procedure is established.
2,551 citations
Columbia University1, George Washington University2, University of Texas Health Science Center at Houston3, University of Alabama at Birmingham4, National Institutes of Health5, University of Texas Medical Branch6, Brown University7, Ohio State University8, University of Utah9, University of North Carolina at Chapel Hill10, Case Western Reserve University11, Northwestern University12, University of Colorado Boulder13, Duke University14, Stanford University15, University of Texas Southwestern Medical Center16, University of Pittsburgh17, Oregon Health & Science University18, Wayne State University19, Medical University of South Carolina20, Emory University21
TL;DR: Administration of betamethasone to women at risk for late preterm delivery significantly reduced the rate of neonatal respiratory complications and caused no significant between-group differences in the incidence of chorioamnionitis or neonatal sepsis.
Abstract: BackgroundInfants who are born at 34 to 36 weeks of gestation (late preterm) are at greater risk for adverse respiratory and other outcomes than those born at 37 weeks of gestation or later. It is not known whether betamethasone administered to women at risk for late preterm delivery decreases the risks of neonatal morbidities. MethodsWe conducted a multicenter, randomized trial involving women with a singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation who were at high risk for delivery during the late preterm period (up to 36 weeks 6 days). The participants were assigned to receive two injections of betamethasone or matching placebo 24 hours apart. The primary outcome was a neonatal composite of treatment in the first 72 hours (the use of continuous positive airway pressure or high-flow nasal cannula for at least 2 hours, supplemental oxygen with a fraction of inspired oxygen of at least 0.30 for at least 4 hours, extracorporeal membrane oxygenation, or mechanical ventilation) or still...
702 citations
TL;DR: The recommendation of the consensus panel that corticosteroid therapy is indicated for women at risk of premature delivery with few exceptions is well supported by evidence relating to glucocorticoid effects, mechanisms, and pharmacokinetics.
497 citations
TL;DR: Antenatal exposure to betamethasone might result in insulin resistance in adult offspring, but has no clinical effect on cardiovascular risk factors at 30 years of age, and obstetricians should continue to use a single course of antenatal betamETHasone for the prevention of neonatal respiratory distress syndrome.
467 citations
Journal Article•
427 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2025 | 40 |
| 2024 | 94 |
| 2023 | 89 |
| 2022 | 173 |
| 2021 | 94 |
| 2020 | 86 |